- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01155726
The Effect of Masking on Subjective Results During Daily Disposable Contact Lens Studies (ARGON)
June 26, 2012 updated by: CIBA VISION
The purpose of this study is to explore the effect of masking on subjective ratings for two daily disposable contact lenses.
Study Overview
Status
Completed
Intervention / Treatment
- Device: Nelfilcon A contact lens
- Device: Nelfilcon A contact lens with comfort additive (DACP), unmasked
- Device: Nelfilcon A contact lens with comfort additive (DACP), masked
- Device: Etafilcon A contact lens with comfort additive (1DAVM), unmasked
- Device: Etafilcon A contact lens with comfort additive (1DAVM), masked
- Device: Nelfilcon A contact lens with comfort additive (DACP), partially masked
- Device: Etafilcon A contact lens with comfort additive (1DAVM), partially masked
- Device: Etafilcon A contact lens
Study Type
Interventional
Enrollment (Actual)
134
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Waterloo, Ontario, Canada, N2L 3G1
- Centre for Contact Lens Research: University of Waterloo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 17 years of age or older.
- Ocular exam within 2 years.
- Currently wearing soft contact lenses on a daily wear basis.
- Contact lens prescription between +6.00D and -10.00D.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
- Any ocular disease.
- Use of systemic or ocular medications that may affect ocular health.
- Unable to achieve an acceptable fit with the study lenses.
- Anisometropia >1.00D or astigmatism >0.75D.
- Other protocol-defined exclusion criteria may apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nelfilcon A, Masked, Unmasked
Nelfilcon A worn in adaptation phase (bilaterally, 30 days).
Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days.
Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days.
All products worn in a daily wear, daily disposable mode.
|
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and lens packaging visible to participant.
Lenses inserted and removed by participant.
Other Names:
Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use.
Blister pack label and lens packaging visible to participant.
Lenses and removed inserted by participant.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and packaging not visible to participant.
Lenses inserted and removed by the investigator.
Other Names:
Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use.
Blister pack label and lens packaging visible to participant.
Lenses inserted and removed by participant.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and packaging not visible to participant.
Lenses inserted and removed by the investigator.
Other Names:
|
Active Comparator: Nelfilcon A, Masked, Partially Masked
Nelfilcon A worn in adaptation phase (bilaterally, 30 days).
Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days.
Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days.
All products worn in a daily wear, daily disposable mode.
|
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and lens packaging visible to participant.
Lenses inserted and removed by participant.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and packaging not visible to participant.
Lenses inserted and removed by the investigator.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and packaging not visible to participant.
Lenses inserted and removed by the investigator.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Lens name and manufacturer on blister pack label concealed from participant.
Lenses inserted and removed by the participant.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Lens name and manufacturer on blister pack label concealed from participant.
Lenses inserted and removed by the participant.
Other Names:
|
Active Comparator: Etafilcon A, Masked, Unmasked
Etafilcon A worn in adaptation phase (bilaterally, 30 days).
Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days.
Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days.
All products worn in a daily wear, daily disposable mode.
|
Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use.
Blister pack label and lens packaging visible to participant.
Lenses and removed inserted by participant.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and packaging not visible to participant.
Lenses inserted and removed by the investigator.
Other Names:
Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use.
Blister pack label and lens packaging visible to participant.
Lenses inserted and removed by participant.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and packaging not visible to participant.
Lenses inserted and removed by the investigator.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and lens packaging visible to participant.
Lenses inserted and removed by participant.
Other Names:
|
Active Comparator: Etafilcon A, Masked, Partially Masked
Etafilcon A worn in adaptation phase (bilaterally, 30 days).
Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days.
Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days.
All products worn in a daily wear, daily disposable mode.
|
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and packaging not visible to participant.
Lenses inserted and removed by the investigator.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and packaging not visible to participant.
Lenses inserted and removed by the investigator.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Lens name and manufacturer on blister pack label concealed from participant.
Lenses inserted and removed by the participant.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Lens name and manufacturer on blister pack label concealed from participant.
Lenses inserted and removed by the participant.
Other Names:
Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use.
Blister pack label and lens packaging visible to participant.
Lenses inserted and removed by participant.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Subjective Comfort
Time Frame: Insertion, 4 hours, 8 hours each: Day 1, Day 2, and Day 3
|
Participants were asked, "How would you rate your comfort with your study lenses?" and indicated their response by marking a continuum line ranging from 0=very poor comfort to 100=excellent comfort.
Subjective comfort was collected at three time points (insertion, 4 hours, 8 hours) for 3 days, and the comfort ratings were averaged together.
|
Insertion, 4 hours, 8 hours each: Day 1, Day 2, and Day 3
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Actual)
February 1, 2011
Study Completion (Actual)
February 1, 2011
Study Registration Dates
First Submitted
June 30, 2010
First Submitted That Met QC Criteria
July 1, 2010
First Posted (Estimate)
July 2, 2010
Study Record Updates
Last Update Posted (Estimate)
July 10, 2012
Last Update Submitted That Met QC Criteria
June 26, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P-371-C-101
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myopia
-
He Eye HospitalNot yet recruiting
-
University of BradfordCoopervision, Inc.; University of HuddersfieldNot yet recruiting
-
Visioneering Technologies, IncRecruitingMyopiaUnited States, Canada, Hong Kong, Singapore
-
University Eye Hospital, FreiburgRecruiting
-
Shanghai 10th People's HospitalCompletedMyopia | Myopia, ProgressiveChina
-
Tianjin Eye HospitalActive, not recruiting
-
Tianjin Eye HospitalCompleted
-
Sultan Qaboos UniversityChristian Medical College, Vellore, IndiaUnknown
-
Peking University People's HospitalUnknownProgressive MyopiaChina
-
Shanghai Eye Disease Prevention and Treatment CenterNot yet recruiting
Clinical Trials on Nelfilcon A contact lens
-
CIBA VISIONCompleted
-
CIBA VISIONCompleted
-
CIBA VISIONCompleted
-
CIBA VISIONCompletedAstigmatism | Myopia
-
Alcon ResearchCompletedRefractive Error | Presbyopia | Myopia | Ametropia
-
CIBA VISIONCompleted
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Visioncare Research Ltd.Completed